Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers June 10, 2021

Stay Up To Date With Our News & Insights

Stay informed with current news about our portfolio companies, events and industry insights.

You are subscribed to our newsletters

Oops! Something went wrong while submitting the form.

CincyTech is a venture capital firm that invests in innovative founders tackling the world's complex challenges. Our experienced team is fluent in the language of founders, researchers, and inventors working with deep domain expertise and market foresight. We partner early to help transform ideas into world-class companies.

2900 Reading Rd. Ste. 410 Cincinnati, OH 45206

Contact CincyTech

Home Approach Portfolio Team Community News & Insights Pitch Us

Careers University Programs Disclosures

Made by 5Four Digital®

Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers June 10, 2021

Recent Blogs

Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval

Kurome Therapeutics Targets Dysregulated Immune Signaling in Blood Cancer Patients

Eyas™ Medical Imaging Brings State-of-the-Art MRI to NICUs, Revolutionizing Access for Fragile Newborns

Stay Up To Date With Our News & Insights